Life Science Research Institute, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Laboratory for Infectious Disease Prevention, Korea Zoonosis Research Institute, Jeonbuk National University, Iksan 54531, Republic of Korea.
Mol Ther. 2023 Jun 7;31(6):1675-1687. doi: 10.1016/j.ymthe.2023.03.018. Epub 2023 Mar 21.
CRISPR-Cas13-mediated viral genome targeting is a novel strategy for defending against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Here, we generated mRNA-encoded Cas13b targeting the open reading frame 1b (ORF1b) region to effectively degrade the RNA-dependent RNA polymerase gene. Of the 12 designed CRISPR RNAs (crRNAs), those targeting the pseudoknot site upstream of ORF1b were found to be the most effective in suppressing SARS-CoV-2 propagation. Pseudoknot-targeting Cas13b reduced expression of the spike protein and attenuated viral replication by 99%. It also inhibited the replication of multiple SARS-CoV-2 variants, exhibiting broad potency. We validated the therapeutic efficacy of this system in SARS-CoV-2-infected hACE2 transgenic mice, demonstrating that crRNA treatment significantly reduced viral titers. Our findings suggest that the pseudoknot region is a strategic site for targeted genomic degradation of SARS-CoV-2. Hence, pseudoknot-targeting Cas13b could be a breakthrough therapy for overcoming infections by SARS-CoV-2 or other RNA viruses.
CRISPR-Cas13 介导的病毒基因组靶向是一种针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)变体的新型策略。在这里,我们生成了靶向开放阅读框 1b(ORF1b)区域的 mRNA 编码 Cas13b,以有效降解 RNA 依赖性 RNA 聚合酶基因。在设计的 12 个 CRISPR RNA(crRNA)中,靶向 ORF1b 上游假结位点的 crRNA 被发现最有效地抑制 SARS-CoV-2 的传播。假结靶向 Cas13b 降低了刺突蛋白的表达,并将病毒复制减少了 99%。它还抑制了多种 SARS-CoV-2 变体的复制,表现出广泛的效力。我们在感染 SARS-CoV-2 的 hACE2 转基因小鼠中验证了该系统的治疗效果,表明 crRNA 治疗显著降低了病毒滴度。我们的研究结果表明,假结区域是针对 SARS-CoV-2 靶向基因组降解的战略位点。因此,假结靶向 Cas13b 可能是克服 SARS-CoV-2 或其他 RNA 病毒感染的突破性治疗方法。